Short Interest in Certara, Inc. (NASDAQ:CERT) Expands By 18.7%

Certara, Inc. (NASDAQ:CERT) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 5,260,000 shares, a growth of 18.7% from the January 15th total of 4,430,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the short-interest ratio is currently 4.2 days. Approximately 4.7% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Robert W. Baird lowered their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Barclays decreased their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus price target of $15.92.

Certara Trading Down 0.4 %

CERT stock traded down $0.06 during midday trading on Friday, hitting $14.19. 2,074,445 shares of the company’s stock were exchanged, compared to its average volume of 1,319,967. The stock’s fifty day moving average price is $12.10 and its 200-day moving average price is $11.72. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The company has a market cap of $2.28 billion, a PE ratio of -70.95, a price-to-earnings-growth ratio of 9.33 and a beta of 1.57. Certara has a one year low of $9.41 and a one year high of $19.87.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently bought and sold shares of CERT. Brown Brothers Harriman & Co. acquired a new position in Certara during the third quarter worth approximately $27,292,000. Wasatch Advisors LP increased its position in Certara by 22.4% during the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after buying an additional 1,651,076 shares during the last quarter. Bank of New York Mellon Corp increased its position in Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock worth $21,248,000 after buying an additional 1,253,385 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in Certara by 40.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after buying an additional 1,128,006 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Certara in the fourth quarter valued at approximately $11,542,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.